NEW ORLEANS, Sept. 22, 2017 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that theyhave until October 23, 2017 to file lead plaintiff applications in a securities class action lawsuit against Teva Pharmaceutical Industries Limited (NYSE: TEVA), if they purchased the Company's American Depository
Teva Pharmaceutical investors should visit us at https://www.claimsfiler.com/cases/view-teva-pharmaceutical-industries-ltd-american-depository-shares-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Teva Pharmaceutical and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 3, 2017, Teva disclosed the recording of a goodwill impairment charge of $6.1 billion for Q2 2017 related to the acquisition of Actavis Generics as a result of poor performance in its U.S. generics sector, as well as lower overall expected poor performance due to increased competition and delays in product launches.
On this news, the price of Teva Pharmaceutical's shares plummeted.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
View original content:http://www.prnewswire.com/news-releases/teva-pharmaceutical-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-teva-pharmaceutical-industries-limited---teva-300524202.html
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All